Medicenna rises on promising pre-clinical data for cancer therapy

Medicenna Therapeutics

08/04/2022 15:40

** Shares of drug developer  MDNA.O  rise 2.5% to $1.23
    ** Co reports pre-clinical data highlighting potent
anti-tumor efficacy of its next-generation immunotherapy
candidate
    ** Data presented at American Association for Cancer
Research annual meeting
    ** All four brokerages covering the sto9ck rate it 'buy' or
higher; their median PT is $9
    ** Stock down ~24% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))